The Emerging Role of GLP-1 Agonists in Burn Care: What Do We Know?

Autor:	Manasyan A; Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA., Cannata B; Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA., Ross E; Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA., Lasky S; Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA., Stanton EW; Division of Plastic and Reconstructive Surgery, Keck School of Medicine, Los Angeles, CA, 90033, USA., Malkoff N; Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA., Collier Z; Division of Plastic and Reconstructive Surgery, Keck School of Medicine, Los Angeles, CA, 90033, USA., Johnson MB; Division of Plastic and Reconstructive Surgery, Keck School of Medicine, Los Angeles, CA, 90033, USA., Gillenwater TJ; Division of Plastic and Reconstructive Surgery, Keck School of Medicine, Los Angeles, CA, 90033, USA.
Jazyk:	angličtina
Zdroj:	Journal of burn care & research : official publication of the American Burn Association [J Burn Care Res] 2024 Oct 15. Date of Electronic Publication: 2024 Oct 15.
DOI:	10.1093/jbcr/irae189
Abstrakt:	Glucagon-like peptide-1 (GLP-1) agonists mimic the action of GLP-1, a hormone that regulates blood glucose levels via stimulation of insulin release and inhibition of glucagon secretion. After burn, the current literature suggests that the use of GLP-1 agonists results in less insulin dependence with similar glucose control and hypoglycemic events to patients receiving a basal-bolus insulin regimen. GLP-1 agonists may also promote wound healing through various mechanisms including angiogenesis and improved keratinocyte migration. Despite the potential benefits, GLP-1 agonists reduce gastrointestinal motility which impacts their widespread adoption in burn care. This dysmotility can result in inadequate nutrition delivery, unintentional weight loss, and is a potential aspiration risk. The net impact of these medications on burn patients is unclear. Given their potential to demonstrate the safety, efficacy, and optimal dosing of various GLP-1 agonists in acute burn management. (© The Author(s) 2024. Published by Oxford University Press on behalf of the American Burn Association. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu